Market Place
Sourcing Support
Adverum Biotechnologies Q2 2025 Financial Results and Highlights
12 Aug 2025 //
GLOBENEWSWIRE
Adverum Biotech joins H.C. Wainwright Ophthalmology Conference
06 Aug 2025 //
GLOBENEWSWIRE
Adverum Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
05 Jun 2025 //
GLOBENEWSWIRE
Adverum To Participate In H.C. Wainwright Ophthalmology Conference
02 Aug 2024 //
GLOBENEWSWIRE
Adverum Presents Positive Ixo-vec Data At ASRS Meeting
17 Jul 2024 //
GLOBENEWSWIRE
Adverum To Participate In TD Cowen’s Genetic Medicines Summit
18 Jun 2024 //
GLOBENEWSWIRE
Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as CMO
11 Jun 2024 //
GLOBENEWSWIRE
Adverum Announces Positive Safety Data from LUNA Phase 2 Trial of Ixo-vec
08 Feb 2024 //
GLOBENEWSWIRE
Adverum will Host Webcast to Review LUNA Phase 2 Efficacy and Safety Results
01 Feb 2024 //
GLOBENEWSWIRE
Adverum Bio Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer
29 Jan 2024 //
GLOBENEWSWIRE
Adverum Announces 3-Year Efficacy Results from the OPTIC Extension Study
04 Nov 2023 //
GLOBENEWSWIRE
Adverum Completes Enrollment of Phase 2 LUNA Trial in Wet AMD
10 Aug 2023 //
GLOBENEWSWIRE
Adverum Presents Data at ARVO Supporting Bilateral Administration of Ixo-vec
23 Apr 2023 //
GLOBENEWSWIRE
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18 Jan 2023 //
GLOBENEWSWIRE
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06 Dec 2022 //
GLOBENEWSWIRE
Adverum Biotechnologies Presents +VE End of Study Results from the OPTIC Trial
04 Nov 2022 //
GLOBENEWSWIRE
Adverum Biotechnologies Announces Upcoming Data Presentation The Retina Society
27 Oct 2022 //
ADVERUM
Adverum Presents Anatomical Improvements in Intraretinal and Subretinal
30 Sep 2022 //
GLOBENEWSWIRE
Adverum to Participate in the Chardan 6th Annual Genetic Medicines
27 Sep 2022 //
GLOBENEWSWIRE
Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022
23 Sep 2022 //
GLOBENEWSWIRE
Adverum to Participate in the Jefferies Cell and Genetic Medicine Summit
23 Sep 2022 //
GLOBENEWSWIRE
Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Ph2
14 Sep 2022 //
GLOBENEWSWIRE
Adverum Biotechnologies to Participate in the H.C. Wainwright 24th Annual
08 Sep 2022 //
GLOBENEWSWIRE
Adverum to Present at Inaugural Gilmartin Group Emerging Growth Company Showcase
26 Aug 2022 //
GLOBENEWSWIRE
Adverum Biotechnologies Reports Second Quarter 2022 Financial Results
11 Aug 2022 //
GLOBENEWSWIRE
Adverum to Participate in the 2nd Annual H.C. Wainwright Ophthalmology
10 Aug 2022 //
GLOBENEWSWIRE
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 Aug 2022 //
GLOBENEWSWIRE
Adverum Bio Presents Analyses After a Single IVT Injection of ADVM-022 (Ixo-vec)
15 Jul 2022 //
GLOBENEWSWIRE
Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022
08 Jul 2022 //
GLOBENEWSWIRE
Adverum lays off staff, funnels cash to single eye candidate
08 Jul 2022 //
FIERCEBIOTECH
Adverum Bio Completes IND Amendment, Initiates PII Trial of ADVM-022 in Wet AMD
06 Jul 2022 //
GLOBENEWSWIRE
Adverum Bio Granted PRIME Designation by EMA for ADVM-022 in Wet AMD
24 Jun 2022 //
GLOBENEWSWIRE
Adverum Biotechs Presents 3-Year Aflibercept Protein Expression and Improvement
09 Jun 2022 //
GLOBENEWSWIRE
Adverum Bio Announces New Data at the Macula Society`s 2022 Annual Meeting
02 Jun 2022 //
GLOBENEWSWIRE
Adverum Presents Data at ASGCT Supporting PII Development Plans for ADVM-022
17 May 2022 //
GLOBENEWSWIRE
Adverum Biotechnologies Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09 May 2022 //
GLOBENEWSWIRE
Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2022
02 May 2022 //
GLOBENEWSWIRE
Adverum Bio Presents Additional Efficacy and Safety Data of ADVM-022 at ARVO
01 May 2022 //
GLOBENEWSWIRE
Adverum Biotechnologies Announces Upcoming Data Presentations at ARVO 2022
19 Apr 2022 //
GLOBENEWSWIRE
Adverum Bio Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD
06 Apr 2022 //
GLOBENEWSWIRE
Adverum Bio Reports Fourth Quarter and Full Year 2021 Financial Results
29 Mar 2022 //
GLOBENEWSWIRE
Adverum Appoints Rabia Gurses Ozden and Soo J. Hong to Board of Directors
17 Mar 2022 //
GLOBENEWSWIRE
Adverum Biotech to Participate in the 42nd Annual Cowen Healthcare Conference
28 Feb 2022 //
GLOBENEWSWIRE
Adverum Biotechnologies Appoints Star Seyedkazemi as Chief Development Officer
06 Jan 2022 //
GLOBENEWSWIRE
Adverum Bio Granted ODD by FDA for Gene Therapy Candidate in PC Development
04 Jan 2022 //
GLOBENEWSWIRE
Gyroscope spins the wheel again as it taps Sanofi for $60M
09 Nov 2021 //
PHARMAPHORUM
Adverum Presents Clinical Data on ADVM-022 at the American Society
09 Oct 2021 //
GLOBENEWSWIRE
Adverum Presents 2-Year OPTIC Demonstrating Sustained Durability Inj of ADVM-022
01 Oct 2021 //
GLOBENEWSWIRE
Adverum to Present Data from ADVM-022 Clinical Trials Medical Conferences
27 Sep 2021 //
GLOBENEWSWIRE
Adverum Appoints Jim Wang, as Senior VP, Head of Regulatory Affairs
23 Aug 2021 //
GLOBENEWSWIRE
Adverum Reports Second Quarter 2021 Results
05 Aug 2021 //
GLOBENEWSWIRE
electroCore Announces Second Quarter 2021 Financial Results
05 Aug 2021 //
GLOBENEWSWIRE
Adverum Faces Rocky Road As It Switches Gears From DME To Wet AMD
26 Jul 2021 //
SCRIP
Adverum faces murky future after review turns up deeper safety issues
23 Jul 2021 //
ENDPTS
Adverum ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema
22 Jul 2021 //
GLOBENEWSWIRE
Adverum ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema
22 Jul 2021 //
GLOBENEWSWIRE
A serious side effect puts a biotech`s eye gene therapy in limbo
30 Apr 2021 //
BIOPHARMADIVE
Adverum shares halved after trial patient goes blind in one eye
29 Apr 2021 //
FIERCE BIOTECH
Adverum Provides Update on the INFINITY Trial Evaluating ADVM-022
28 Apr 2021 //
PRESS RELEASE
